English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Semaglutide (glucagon-like peptide-1 receptor-agonist, GLP-1RA) has shown nephroprotective effects in previous cardiovascular studies. However its efficacy and safety in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been scarcely studied. Materials and methods this is a multicenter, retrospective, observational study in patients with T2D and CKD with A1c glycosylated haemoglobin (HbA1c) between 7.5-9.5% treated with subcutaneous semaglutide for 12 months in real-world clinical practice. Main objectives were glycemic control as HbA1c&amp;lt;7% and weight loss of &amp;gt;5%. Results 122 patients, age 65.50±11years, 62% men. Duration of T2D: 12 years and baseline HbA1c: 7.57%±1.36%, eGFR: 50.32±19.21 ml/min/1.73m2; 54% had albumin-to-creatinine ratio (UACR):30-300 mg/g and 20% UACR &amp;gt;300 mg/g. After 12 months of follow up: HbA1c declined -0.73%±1.09%(p&amp;lt;0.001) with 57% of patients achieving values &amp;lt;7%; weight loss -6.95 kg(p&amp;lt;0.001) with 59% of patients showing reduction&amp;gt;5% of their body weight. Systolic and diastolic blood pressure decreased -9.85 mmHg and -5.92 mmHg, respectively(p&amp;lt;0.001). The mean UACR reduced 51% in the group with baseline macroalbuminuria (UACR)&amp;gt;300 mg/g. Mean eGFR (by CKD-EPI) remained stable. The needs of basal insulin decreased 20% (p&amp;lt;0.005). Only 7% of patients on insulin had mild hypoglycemic episodes. Semaglutide was stopped in 5.7% of patients for digestive intolerance. Conclusions In this real-world study, patients with T2D and CKD treated with subcutaneous semaglutide for 12 months significantly improved glycemic control and decreased weight. Albuminuria decreased by &amp;gt;50% in patients with macroalbuminuria. The administration of GLP-1RA in patients with T2D and CKD was safe and well tolerated.

Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice